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Abstract MafBx and Murf are two new rat E3 ubiquitin li-
gases induced in muscle atrophy. Our goal was to investigate
whether lipopolysaccharide (LPS) injection, a model of muscle
catabolism, is associated with increased expression of MafBx
and Murf. LPS (750 Wg/100 g body weight) induces MafBx and
Murf mRNA (respectively, 23-fold and 33-fold after 12 h;
P6 0.001). A transient induction of tumor necrosis factor-K
mRNA (21-fold; P6 0.001 at 3 h) and a decrease of insulin
like growth factor-I mRNA (50%; P6 0.001 at 6 h), two po-
tential regulators of the ubiquitin^proteasome system were also
demonstrated. In summary, MafBx and Murf mRNA are up-
regulated in response to LPS and might play a role in the
muscle proteolysis observed.
5 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Muscle wasting is a common complication of many hyper-
catabolic states such as sepsis, cancer and polytrauma [1,2].
Although reduced protein synthesis contributes to the de-
crease in muscle protein content [3^5], increased myo¢brillar
protein breakdown seems to play the major role in this muscle
loss [6]. Myo¢brillar protein degradation caused by sepsis is
thought to be mediated essentially through the activation of
the ubiquitin^proteasome proteolytic system. In this process,
the ubiquitin (Ub) is activated by an ubiquitin-activating en-
zyme (E1 family) [7] and conjugated through the ubiquitin-
conjugating enzymes (E2 family) [8] to the protein to be de-
graded. In most cases, the presence of a third protein, the
ubiquitin protein ligase (E3 family) [7,9], is required to stabi-
lize the protein^Ub complex. The muscle expression of ubiq-
uitin, E214kDa and E3-K has been reported to be increased
during sepsis [10^12]. Two new ubiquitin ligases have been
recently identi¢ed, the mouse atrophy gene-1 [13] (atrogin-1)
also described as the rat muscle atrophy F-box (MafBx) [14],
and the rat muscle RING ¢nger 1 (Murf) [14]. By contrast to
the ubiquitin [15] and E214kDa [16], these enzymes are muscle
speci¢c and therefore are thought to be speci¢cally involved in
myo¢brillar protein degradation. The MafBx and Murf li-
gases are indeed strongly increased during muscle atrophy
such as following prolonged immobilization, denervation,
treatment with glucocorticoids and under weighting by sus-
pension [14]. However, the regulation of these two new ubiq-
uitin ligases by sepsis has not yet been assessed. Therefore, as
a ¢rst step in this direction, we used a classical rat lipopoly-
saccharide (LPS) model mimicking sepsis to investigate
whether the acute in£ammation caused by LPS is associated
with an increased expression of MafBx and Murf in the skel-
etal muscle. Although it may be argued that intraperitoneal
injection of LPS is not a proper model of sepsis, the method is
nonetheless an accepted model of septic shock [17]. Because
muscle proteolysis, in particular activation of the ubiquitin^
proteasome system, has been reported to be regulated by tu-
mor necrosis factor (TNF)-K and insulin like growth factor
(IGF)-I, we assessed in parallel the expression of these two
molecules into the muscle [18^21].
2. Materials and methods
2.1. Experimental design
Fifty male Wistar rats (8 weeks old, 218F 9 g, Katholieke Univer-
siteit of Leuven, Leuven, Belgium) were maintained for 1 week under
standardized conditions of light (12 h light/12 h dark cycle) and tem-
perature (22F 2‡C). Access to animals chow was available only be-
tween 6:00 p.m. and 9:00 a.m., whereas access to water was unre-
stricted. The morning of the eighth day, the rats were randomly
divided in three di¡erent groups: control (non-injected, n=4), LPS
(n=30) and saline (n=16). The LPS and saline groups were injected
intraperitoneally respectively with LPS (750 Wg/100 g body weight,
Sigma, St. Louis, MO, USA) or an equivalent volume of saline bu¡er.
The control group was immediately sacri¢ced (0 h). The LPS and the
time-matched saline groups were sacri¢ced after 1, 3, 6 and 12 h.
Tibialis anterior muscles were dissected, snap frozen in liquid nitrogen
and stored at 380‡C until processing.
2.2. Real-time quantitative polymerase chain reaction (RTQ-PCR)
Total RNA was prepared from snap frozen tissue samples (400 mg)
using TRIzol0 (Gibco Life Technologies, Paisley, UK). RNA was
quanti¢ed by spectrophotometry (V=260 nm) and its concentration
adjusted to 0.25 Wg/Wl using RNase free water. Reverse transcription
(RT) was performed using the GeneAmp PCR system 2400 (Applied
Biosystem, Foster City, CA, USA) with 1 Wg of total RNA in a
reaction volume of 20 Wl, containing 7.5 WM random hexamers, RT
bu¡er 1U, 9 mM dithiothreitol, 220 WM of each deoxyribonucleotide
triphosphate (dNTP), 20 U of ribonuclease inhibitor (Applied Biosys-
tem) and 50 U of reverse transcriptase (Superscript0, Gibco BRL).
Final RT product was adjusted to 40 Wl using RNase free water.
RTQ-PCR primers were designed (Primer Express Software, Applied
Biosystem) for rat Ub, E214kDa, MafBx, Murf, IGF-I, TNF-K and
GAPDH. The primers (Table 1) were produced on an automated
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synthesizer (Applied Biosystem) according to the manufacturer’s pro-
tocol. Sybr Green0 RTQ-PCR analyses were carried out using the
GeneAmp 5700 (Applied Biosystem). RTQ-PCR was carried out us-
ing the following cycle parameters: 10 min at 95‡C, followed by 40
cycles of 1 min at 60‡C and 15 s at 95‡C. For each gene, RTQ-PCR
was conducted in duplicate with a 25 Wl reaction volume of 5 ng of
cDNA, 2.5 Wl Sybr Green0 bu¡er, 250 WM dNTP, 3 mM MgCl2, 400
nM of each primers and 0.625 U amp Taq Gold0 Polymerase (Ap-
plied Biosystem). To ensure the quality of the measurements, each
plate included for each gene a negative control (sample replaced by
RNase free water) and a positive control consisting in a pool of
cDNA from positive samples. The threshold cycle (Ct) from a positive
sample was used to calculate the inter-assay coe⁄cient of variation
(CV). For each gene, the CV was calculated as standard deviation/
mean of the Ct determined on ¢ve di¡erent plates and with di¡erent
mixes. The CVs obtained were 4%, 5%, 8%, 6%, 8%, 7% and 6%, for
Ub, E214kDa, MafBx, Murf, IGF-I, TNF-K and GAPDH, respectively.
2.3. Statistical analysis and results presentation
Results were expressed using the comparative cycle threshold (Ct)
method as described in the User Bulletin #2 from the manufacturer
(Applied Biosystem). The vCt values were calculated in every sample
for each gene of interest as followed: Ctgene of interest3Ctreporter gene with
GAPDH as the reporter gene. The calculation of the relative changes
in the expression level of one speci¢c gene (vvCt) was performed by
subtraction of the vCt from the control group (0 h, used as a cali-
brator) to the corresponding vCt (at di¡erent time) from the LPS or
the saline groups [22]. The values and ranges given in Fig. 1 were
determined as followed: 23vvCt with vvCt+S.E.M. and vvCt3
S.E.M., where S.E.M. is the standard error of mean of the vvCt value
(User Bulletin #2, Applied Biosystem).
Statistical analysis for the gene expression levels assessed by RTQ-
PCR was performed using an unpaired t-test to compare the vCt
values from the LPS and saline groups at each time point. Di¡erences
were considered statistically signi¢cant for P6 0.05.
3. Results
Our data show that LPS injection stimulates the muscle
gene expression of all the four components of the ubiquitin^
proteasome system investigated. After LPS injection, the
mRNA levels of these four genes (Ub, E214kDa, MafBx and
Murf) increased gradually with time, but with di¡erent ampli-
tude and kinetics (Fig. 1). The ubiquitin mRNA levels raised
as early as 3 h after LPS injection to reach a maximal value
at 12 h, the last time point investigated (8.3-fold induction
vs saline, P6 0.001). In contrast, the increase in E214kDa
mRNA levels was only observed 12 h after LPS injection
(3.0-fold, P6 0.001). But, the most dramatic changes were
observed for the two recently described ubiquitin ligases,
MafBx and Murf. LPS injection caused a rapid and gradual
increase in MafBx (1.6-fold, P6 0.001 at 3 h and 4.3-fold,
P6 0.001 at 6 h) with a maximum at 12 h, the last point
examined (23-fold induction; P6 0.001). The Murf mRNA
stimulation by LPS was parallel to that of MafBx mRNA,
but even stronger with a maximal induction of 33.1-fold at
12 h (P6 0.001). In an attempt to de¢ne the mediators re-
sponsible for these changes, we assessed in parallel the gene
expression levels of IGF-I and TNF-K in muscle after LPS
injection. These two factors have indeed been demonstrated to
regulate the gene expression of several components of the
ubiquitin^proteasome system in the muscle [23^26]. IGF-I
mRNA levels progressively declined in response to LPS injec-
tion with a nadir at 6 h and 12 h (350%, P6 0.001 and
360%, P6 0.001). In contrast, TNF-K mRNA increased rap-
idly (peak at 1 h) and dramatically (21-fold, P6 0.001) to
persist at lower levels until 12 h, the last point examined
(3.6-fold, P6 0.001) (Fig. 1).
4. Discussion
Our study showed that in£ammation induced by LPS in-
jection dramatically induces the muscle gene expression of
MafBx and Murf, two recently described ubiquitin ligases
considered to play a major role in muscle atrophy [14]. As
previously reported [10,12], sepsis increases other components
of the ubiquitin^proteasome system, namely Ub itself and
E214kDa. However, the role of their induction in the acceler-
ation of proteolysis caused by sepsis is uncertain. In contrast,
a number of ¢ndings indicate that the two E3 ligases (MafBx
and Murf) play a major role in the skeletal muscle proteolysis
during muscle atrophy. First, the expression of MafBx and
Murf, which is increased in most models of muscle atrophy, is
limited to skeletal muscle [14], in contrast to ubiquitin and
E214kDa [15]. Second, MafBx and Murf knockout mice are
more resistant than there wild littermates to muscle atrophy
following denervation, a classical model of muscle atrophy
[14]. In contrast, muscle proteolysis caused by fasting is not
attenuated in E214kDa knockout mice [27]. Finally, the over-
expression of MafBx in C2C12 myotubes induces cell atrophy
[14]. Together with our ¢ndings, these observations indicate
that the dramatic increase in the expression of these two ubiq-
uitin ligases might contribute to the muscle proteolysis caused
by sepsis.
Table 1
Gene sequences used as forward and reverse primers for RTQ-PCR
Gene Sequence 5P^3P Amplicon (bp)
Ubiquitin Forward primer GAT CCA GGA CAA GGA GGG C 71
Reverse primer CAT CTT CCA GCT GCT TGC CT
E214kDa Forward primer TCC TGC AGA ACC GAT GGA G 77
Reverse primer CGG CTC ATC CAA CAG AGA CTG
MafBx Forward primer CCA TCA GGA GAA GTG GAT CTA TGT T 75
Reverse primer GCT TCC CCC AAA GTG CAG TA
Murf1 Forward primer TGT CTG GAG GTC GTT TCC G 59
Reverse primer ATG CCG GTC CAT GAT CAC TT
IGF-I Forward primer GCT ATG GCT CCA GCA TTC G 63
Reverse primer TCC GGA AGC AAC ACT CAT CC
TNF-K Forward primer GCC ACC ACG CTC TTC TGT CT 101
Reverse primer GTC TGG GCC ATG GAA CTG AT
GAPDH Forward primer TGC ACC ACC AAC TGC TTA 72
Reverse primer GGA TGC AGG GAT GAT GTT C
Last column indicates the length of amplicon (bp).
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The mechanisms of the activation of muscle MafBx and
Murf by LPS are not yet unravelled. It is unlikely that these
changes may be due to the anorexia caused by LPS, since
both LPS-injected and saline-treated animals fasted through-
out the day of the experience. Previous reports showed that
TNF-K is able to stimulate proteolysis and the muscle Ub
gene expression [25,26,28]. Furthermore, inhibition of TNF-
K by torbafylline inhibits enhanced skeletal muscle ubiquitin^
proteasome-dependent proteolysis in septic rats [29]. There-
fore, given its strong induction in the muscle of LPS-treated
rats, TNF-K could be responsible for the increase in MafBx
and Murf mRNA observed in this catabolic model. IGF-I has
been reported to inhibit muscle proteolysis in several catabolic
animal models [30,31]. Since IGF-I mRNA levels are de-
creased in the muscle of LPS-treated rats [21], it could be
hypothesized that the reduction of the muscle IGF-I can be
at least partially responsible for the increase in MafBx and
Murf. Although IGF-I blunts the increased expression of sev-
eral components of the ubiquitin^proteasome system such as
Ub and E214kDa in septic rats [32], the possibility for IGF-I to
inhibit the induction of these two new ubiquitin ligases by
LPS is still unknown. Finally, because the activation of the
ubiquitin^proteasome system by sepsis is glucocorticoid-de-
pendent [33,34], it is likely that induction of MafBx and
Murf by LPS may be mediated by increased glucocorticoids.
This hypothesis is supported by the recent observation that
exogenous dexamethasone strongly induces the muscle expres-
sion of these two ligases in mice [14]. Further experiments will
have to delineate the role of IGF-I, TNF-K and glucocorti-
coids in the induction of these E3 ligases during sepsis. In
conclusion, we showed that LPS injection in rat causes induc-
tion of MafBx and Murf, two recently described ubiquitin
ligases speci¢cally expressed in muscle and required for skel-
etal muscle atrophy. Further experiments will have to test
whether their induction is mediated by the parallel decrease
in IGF-I and increase in TNF-K expression into muscle.
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